A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device.

Journal: International journal of clinical oncology
PMID: 39714567

Abstract

BACKGROUND: The implementation of cancer precision medicine in Japan is deeply intertwined with insurance reimbursement policies and requires case-by-case reviews by Molecular Tumor Boards (MTBs), which impose considerable operational burdens on healthcare facilities. The extensive preparation and review times required by MTBs hinder their ability to efficiently assess comprehensive genomic profiling (CGP) test results. Despite attempts to optimize MTB operations, significant challenges remain. This study aims to evaluate the effectiveness of QA Commons, an artificial intelligence-driven system designed to improve treatment planning using CGP analysis. QA Commons utilizes a comprehensive knowledge base of drugs, regulatory approvals, and clinical trials linked to genetic biomarkers, thereby enabling the delivery of consistent and standardized treatment recommendations. Initial assessments revealed that the QA Commons' recommendations closely matched the ideal treatment recommendations (consensus annotations), outperforming the average results of MTBs at Cancer Genomic Medicine Core Hospitals.

Authors

  • Hideaki Bando
    Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Yoichi Naito
    Department of General Internal Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Tomoyuki Yamada
    Genomedia Inc, 4-1-4 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
  • Takao Fujisawa
    Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Mitsuho Imai
    Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Yasutoshi Sakamoto
    Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Yusuke Saigusa
    Department of Biostatistics, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan.
  • Kouji Yamamoto
    Department of Biostatistics, School of Medicine, Yokohama City University, Yokohama, Japan.
  • Yutaka Tomioka
    Department for the Promotion of Medical Device Innovation, National Cancer Center Hospital East, 6- 5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Nobuyoshi Takeshita
    Department of Colorectal Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-City, Chiba, 277-8577, Japan. ntakeshi@east.ncc.go.jp.
  • Kuniko Sunami
    Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Megumi Futamura
    Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Chiemi Notake
    Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Satoko Aoki
    Genomedia Inc, 4-1-4 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
  • Kazunori Okano
    Genomedia Inc, 4-1-4 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
  • Takayuki Yoshino
    National Cancer Center Hospital East, Chiba, Japan.

Keywords

External Resources

Popular Topics
Recent Journals